Kiniksa sees FY25 ARCALYST net product revenue $590M-$605M

Kiniksa (KNSA) expects 2025 ARCALYST net product revenue of between $590 million and $605 million, compared to prior guidance of between $560 million and $580 million. Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Kiniksa continues to monitor potential implications of tariffs on pharmaceuticals imported into the United States. ARCALYST is currently manufactured in the United States by Regeneron Pharmaceuticals. Kiniksa has been in the process of transferring drug substance manufacturing to Samsung Biologics in South Korea and believes any future impact to ARCALYST gross margin would be immaterial, limited only to the cost of drug substance imported into the United States.